Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors

Journal of Acquired Immune Deficiency Syndromes

Volumn 29, Issue 1, 2002, Pages 21-31

  Galli, Massimo ^a   Ridolfo, Anna Lisa ^a   Adorni, Fulvio ^a   Gervasoni, Cristina ^a   Ravasio, Laura ^a   Corsico, Laura ^a   Gianelli, Erika ^a   Piazza, Manuela ^a   Vaccarezza, Mauro ^a   Monforte, Antonella D'Arminio ^a   Moroni, Mauro ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Body habitus changes; HIV; Metabolic alterations; Reverse transcriptase inhibitors

Indexed keywords

CD4 ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY BUILD; BODY FAT; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; RISK FACTOR;

EID: 0036151417     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200201010-00003     Document Type: Article

References (46)

1. Fat distribution and metabolic changes in patients with HIV infection
2. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
3. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
4. "Buffalo hump" in men with HIV infection
5. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
6. Lipodystrophy in patients naive to protease inhibitors
7. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving longterm nucleoside analogue therapy
8. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
9. Protease inhibitors and nucleoside analogue reverse transcriptase inhibitors interact to cause subcutaneous fat wasting in patients with HIV infection
10. Lipodystrophy related to NRTI inhibitors in HAART therapy
11. Risk factors for developing lipodystrophy in patients receiving protease inhibitors
12. Lipodystrophy and metabolic disorders in 646 HIV-1-infected patients previously treated with or without a protease inhibitor
13. Prevalence of lipodystrophy in the long-term follow-up of a clinical trial comparing various combinations of nucleoside analogue reverse transcriptase inhibitors, ALBI Trial (ANRS 070)
14. Lipodystrophy in PI-naive patients treated with RTI combinations: Frequency and risk factors
15. Clinical factors related to the severity of fat redistribution in the HIV Outpatient Study (HOPS)
16. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
17. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
18. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients
19. Visceral abdominal-fat accumulation associated with use of indinavir
20. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
21. Proposal for a clinic classification of morphological and metabolic alterations under ART
22. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
23. Diagnosis prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
24. Prevalence of fat deposition and fat atrophy in a cohort of HIV-infected men and women
25. Body habitus assessment in HIV-infected women: A cross-sectional study
26. Gender differences in HIV-associated adipose redistribution syndrome (HARS): An update
27. Gender differences in prevalence of body habitus changes and metabolic complications in HIV+ African American and Latino individuals from Harlem
28. Hypertrophy of the breasts in a patient treated with indinavir
29. Another case of breast hypertrophy in a patient treated with indinavir
30. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: Correlation between dyslipidaemia and steroid hormone alterations
31. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: A prospective cohort study
32. Adipose tissue alterations after starting antiretroviral therapy in naive patients: The LipoICONA study [abstract 134]
33. Lipoatropy fat accumulation, and mixed syndrome in protease inhibitor-naive HIV-infected patients
34. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection
35. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART)
36. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome
37. Cumulative risk for developing hyperlipidemia in HIV-infected patients treated with protease inhibitors
38. Risk of developing metabolic and morphological alterations under antiretroviral therapy according to the drug combinations
39. Protein and energy substrate metabolism in AIDS patients
40. Localized adipose tissue hypertrophy in patients receiving human immunodeficiency virus protease inhibitors
41. Protease inhibitorassociated hyperglycaemia
42. New onset diabetes mellitus associated with use of protease inhibitor
43. Severe diabetes associated with protease inhibitor therapy
44. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy
45. Mean levels and distributions of some cardiovascular risks factors in Italy in the 1970's and the 1980's. The Italian rifle pooling project. Risk factors and life expectancy
46. Cardiovascular risk factors in Italy: An interpretation with reference to the national health plan 1998-2000